NCT03078881 (LUSTRO) is a clinical trial in Crigler-Najjar Syndrome, sponsored by Audentes Therapeutics.

Who is sponsoring NCT03078881?

NCT03078881 is sponsored by Audentes Therapeutics.

What condition does NCT03078881 study?

NCT03078881 studies Crigler-Najjar Syndrome.

Is NCT03078881 still recruiting?

NCT03078881 is currently completed. Last updated 6 February 2019.

Last reviewed 2019-02-06 · How we verify

NCT03078881: LUSTRO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Assessment Study in Crigler-Najjar Syndrome

Completed Last updated 6 February 2019

What this trial tests

trial in Crigler-Najjar Syndrome in 8 participants. Completed in 23 January 2019.

Timeline

10 March 2017

Primary endpoint
23 January 2019

23 January 2019

Quick facts

Lead sponsor	Audentes Therapeutics
Status	Completed
Study type	OBSERVATIONAL
Enrollment	8
Start date	10 March 2017
Primary completion	23 January 2019
Estimated completion	23 January 2019
Sites	4 locations across United Kingdom, United States, Israel

Conditions studied

Crigler-Najjar Syndrome — all drugs for Crigler-Najjar Syndrome →

Sponsor

Audentes Therapeutics

Who can join

1 and older, any sex, with Crigler-Najjar Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Pre-Phase 1 prospective, non-interventional clinical assessment study to evaluate Crigler-Najjar syndrome subjects requiring daily phototherapy, aged 1 year and older.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Crigler-Najjar Syndrome

Currently open trials in the same condition.

NCT06518005 — Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome · Phase 2 · recruiting
NCT03466463 — Gene Therapy for Severe Crigler Najjar Syndrome · NA · recruiting

Other Audentes Therapeutics trials

Trials by the same sponsor.

NCT03223194 — Gene Transfer Clinical Study in Crigler-Najjar Syndrome · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03078881 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Audentes Therapeutics
Last refreshed: 6 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03078881.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing